- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 02.04. | Truist senkt Kursziel für Upstream Bio wegen verzögertem Studienzeitplan | 4 | Investing.com Deutsch | ||
| 02.04. | Truist cuts Upstream Bio stock price target on trial timeline | 2 | Investing.com | ||
| 27.03. | Evercore ISI stuft Upstream Bio wegen fehlender kurzfristiger Katalysatoren herab | 1 | Investing.com Deutsch | ||
| 27.03. | Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts | 1 | Investing.com | ||
| 26.03. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 26.03. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.03. | Upstream Bio presents additional Phase 2 data for verekitug | 5 | Investing.com | ||
| 01.03. | Upstream Bio: Positive Phase-2-Daten für Verekitug, Aktie dennoch unter Druck | 1 | Investing.com Deutsch | ||
| 01.03. | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | 198 | GlobeNewswire (Europe) | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen | |
| 26.02. | Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 13.02. | Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns | 20 | Benzinga.com | ||
| 11.02. | Upstream Bio Shares Plunge 52% Despite Positive Phase 2 Asthma Data | 5 | RTTNews | ||
| 11.02. | Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts | 1 | Benzinga.com | ||
| 11.02. | Upstream Bio-Aktie stürzt nach gemischten Ergebnissen der Phase-2-Asthmastudie ab | 2 | Investing.com Deutsch | ||
| 11.02. | Upstream Bio down despite mid-stage trial win for asthma drug | 1 | Seeking Alpha | ||
| 11.02. | Upstream Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.02. | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | 275 | GlobeNewswire (Europe) | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| 11.02. | Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma | 1 | GlobeNewswire (USA) | ||
| 17.12.25 | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential | 4 | Investing.com | ||
| 17.12.25 | Upstream Bio: Mizuho startet Coverage mit "Outperform" dank Potenzial bei Asthma-Medikament | 1 | Investing.com Deutsch |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,915 | 0,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| IMMUNOVANT | 26,550 | +5,65 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,850 | +4,17 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| PRAXIS PRECISION MEDICINES | 343,21 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,050 | 0,00 % | Vir Biotechnology startet Erweiterungsstudie für Prostatakrebs-Wirkstoff VIR-5500 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,090 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth | WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 44,850 | 0,00 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| EVOTEC | 5,390 | 0,00 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum | EQS-News: Evotec SE
/ Schlagwort(e): Jahresergebnis
Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum
08.04.2026... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,280 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,300 | +2,45 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 14,350 | +0,70 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,040 | +5,25 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,660 | -3,88 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| CG ONCOLOGY | 67,26 | 0,00 % | CG Oncology, Inc. - 8-K, Current Report |
Das Unternehmen UPSTREAM BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,320 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.